IRWD Stock Analysis: Buy, Sell, or Hold?
IRWD - Ironwood Pharmaceuticals, Inc. - Class A
$4.33
0.21 (5.10%)
▲
5d:
+12.76%
30d:
+32.01%
90d:
+11.03%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When IRWD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: IRWD is 8.0% above its trading range ($4.01). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: IRWD is 8.0% above its trading range ($4.01). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$11.22
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$6.96
37.8% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 4.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IRWD is currently trading at $4.33, which is considered extended relative to its 30-day fair value range of $3.36 to $4.01. From a valuation perspective, the stock is trading at a discount (Forward PE: 3.0) compared to its historical average (4.0). Remarkably, the market is currently pricing in an annual earnings decline of 8.8% over the next few years. This pessimistic expectation contrasts with the company's recent 1046.8% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IRWD is in a strong uptrend. The price is approaching resistance at $4.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: IRWD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.10 (+40.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, IRWD is in a strong uptrend. The price is approaching resistance at $4.39. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.1% recently.
Market Sentiment: IRWD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $6.10 (+40.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.36 -
$4.01
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range (+8.0% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.1%)
- BULLISH: Trading 40.9% below Wall St target ($6.10)
- CAUTION: Extended 8.0% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$3.36 -
$4.01
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.49
Resistance Level
$4.39
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.01
Wall Street Target
$6.10
(+40.9%)
Revenue Growth (YoY)
158.9%
Earnings Growth (YoY)
1046.8%
Profit Margin
28.3%
Valuation Discount vs History
-8.8% cheaper
PE vs Historical
3.0 vs 4.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.8%
(market-implied from PE analysis)
1-Year Target
$3.95
(-9%)
2-Year Target
$3.60
(-17%)
3-Year Target
$3.28
(-24%)
3-Yr Target (if PE normalizes)
(PE: 3→4)
$4.37
(+1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 32.1%)
$72.31
(+1570%)
Base:
(SPY PE: 3.0, Growth: 32.1%)
$9.98
(+131%)
Bear:
(PE: 2.6, Growth: 32.1%)
$8.49
(+96%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (7x PE), but valuation improves significantly next year (3x PE) as earnings recover.
Trailing PE: 6.65 | Current EPS (TTM): $0.62
Bull Case
$9.06
(+109%)
Analyst growth 100.0%, PE expands to 7.3
Base Case
$8.24
(+90%)
Market implied 100.0%, PE stable at 6.7
Bear Case
$2.80
(-35%)
Severe decline -20.0%, PE contracts to 5.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 3.0 to 4.0
Stabilization Target:
$5.76
(+33.0%)
PE Expansion Potential:
+33.0%
Share & Embed Analysis
Last updated: July 03, 2026 5:39 PM ET
Data refreshes hourly during market hours. Next update: 6:39 PM
Data refreshes hourly during market hours. Next update: 6:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IRWD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Alexander J Denner
SELL
6730800 shares
2026-03-17
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 63 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 54 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 60 HOLD |
